PLATINUM-REFRACTORY PRIMARY PERITONEAL CARCINOMA
Clinical trials for PLATINUM-REFRACTORY PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-REFRACTORY PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-REFRACTORY PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…
Matched conditions: PLATINUM-REFRACTORY PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
Virus plus immunotherapy shows promise against resistant ovarian cancer
Disease control OngoingThis early-stage trial tests a specially designed virus (TILT-123) that targets and kills cancer cells while also boosting the immune system. It is given together with the immunotherapy drug pembrolizumab (Keytruda) and sometimes chemotherapy, to women with ovarian cancer that no…
Matched conditions: PLATINUM-REFRACTORY PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC